Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Cancer Res. 2021 Feb 11;81(8):2056–2070. doi: 10.1158/0008-5472.CAN-20-1756

Figure 1. SHP2 knockdown promotes cell phenotypes expected to promote and antagonize GBM progression.

Figure 1.

U87MG cells expressing control or SHP2 shRNA were cultured in 21% or 1% oxygen, and treated with 10 μM gefitinib (G) + 3 μM PHA665752 (P), 500 μM temozolomide (TMZ), or DMSO. 48 h after treatments, (A) cell cycle distribution or (B) cell death was measured by flow cytometry. (C) Lysates from cells treated for 6 h were analyzed by HIF-1α western blotting (Fig. S1A) with densitometry. The SHP2 shRNA used in Figure 1, and throughout main figures, corresponds to SHP2 shRNA#1, defined in Materials and Methods. See Fig. S1E–S1G for a comparison of SHP2 shRNA#1 against the non-overlapping shRNA#2. Throughout the panels, error bars indicate mean ± s.e.m. of three replicates; * p < 0.05 for indicated comparisons from Tukey’s post-hoc comparison following three-way ANOVA. For Fig. 1A, comparisons are made for percentage of cells in G1/G0.